Mode
Text Size
Log in / Sign up
Phase 3 Completed N=680 Randomized Quadruple-blind Treatment

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

Source: ClinicalTrials.gov NCT00423657 ↗
Enrolled (actual)
680
Serious AEs
4.4%
Results posted
Nov 2010
Primary outcomePrimary: Clinical Cure Rate at Test of Cure (TOC) (MITT Population) — 291; 289; 25; 28 participants

Summary

The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of complicated skin infections in adults.

Outcome Measures

OutcomeResultp-value
PRIMARY
Clinical Cure Rate at Test of Cure (TOC) (MITT Population)
291; 289; 25; 28; 26; 21
PRIMARY
The Primary Efficacy Outcome Measure Was the Per-subject Clinical Cure Rate at the TOC Visit in the Clinically Evaluable (CE) Populations.
SECONDARY
To Evaluate the Microbiological Success Rate at the TOC Visit
SECONDARY
To Evaluate the Clinical Response at the End of Therapy (EOT) Visit
SECONDARY
To Evaluate the Clinical and Microbiological Response by Pathogen at the TOC Visit
SECONDARY
To Evaluate Clinical Relapse at the Late Follow Up (LFU) Visit
SECONDARY
To Evaluate Microbiological Reinfection or Recurrence at the LFU Visit
SECONDARY
To Evaluate Safety

Eligibility Criteria

Inclusion Criteria

  • Skin and skin structure infection (SSSI) that involves deeper soft tissue or requires significant surgical intervention, or cellulitis or abscess on lower extremity which occurs in subjects with diabetes mellitus or well-documented peripheral vascular disease.

Exclusion Criteria

  • Prior treatment of current complicated skin and skin structure infection (cSSSI) with an antimicrobial.
  • Failure of vancomycin or aztreonam as therapy for the current cSSSI, or prior isolation of an organism with in vitro resistance to vancomycin or aztreonam.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00423657). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search